H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Lisata Therapeutics (LSTA – Research Report) today and set a price target of $15.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Joseph Pantginis has given his Buy rating due to a combination of factors, primarily focusing on Lisata Therapeutics’ strategic collaboration with GATC Health. This partnership is set to enhance drug development by leveraging GATC’s advanced A.I. platform, which is designed to optimize and de-risk the development process for certepetide across multiple indications. The collaboration aims to identify potential new indications with a high likelihood of success, thereby strengthening Lisata’s pipeline.
Furthermore, the collaboration extends to the identification of combination therapies and operational partnerships for GATC’s own drug candidates, including those targeting opioid addiction and other significant health issues. This strategic alliance not only accelerates Lisata’s drug development timeline but also positions the company to benefit financially through milestone fees and royalties from successfully commercialized products. These factors collectively contribute to Pantginis’s confidence in Lisata’s growth potential and justify the Buy rating.